Knocksense: A local content and recommendations platform

{{ subpage.title }}

Lucknow's CSIR-CDRI plans to conduct a state-level serosurvey for COVID antibodies!

In a move to better gauge the state of the pandemic, Lucknow's CSIR-Central Drug Research Institute has decided to augment the scope of COVID serological survey to cover the entire territory of Uttar Pradesh. This assessment is conducted by testing the samples of random individuals for the presence of COVID antibodies. Now, the top-notch research centre has asked the administration to provide more samples, so that a state-level evaluation can be conducted.

Read Now Show less

Lucknow's CDRI finds success in clinical trials of a new drug to be used for treating COVID

In a remarkable breakthrough, Lucknow's Central Drug Research Institute (CDRI) announced the success of clinical trials for Umifenovir, an antiviral drug to be used in the treatment of COVID-19. As per the study conducted on 132 COVID patients, proper doses of the drug, administered twice daily for a period of five days, can ensure significant results. It has been claimed that the drug can lower viral load to zero in mild or moderate symptomatic and asymptomatic patients.

Read Now Show less

Virology labs at Lucknow's CDRI & NBRI now part of Indian Sars Cov-2 Genomic Surveillance Consortium

Premium virology labs at Lucknow's Central Drug Research Institute (CDRI) and National Botanical Research Institute, have been included in the Indian Sars Cov-2 Genomic Surveillance Consortium (INSACOG). This is a grid of 28 laboratories across the country which are collectively studying the variations in the coronavirus genomic makeup. Now the aforementioned labs in Lucknow will also study the mutations of the COVID-19 virus, to mitigate the impact of the expected 'third wave'.

Read Now Show less

Latest